What is CMR Versius?
CMR Versius is a modular soft-tissue surgical robotic system from CMR Surgical, a UK-based company founded in 2014. Per DEPLOY's surgical cluster framework: international commercial soft-tissue surgical archetype with established commercial deployment volume across EU + UK + Australia + India; US FDA clearance state operates at cap-flag posture pending primary-source confirmation of submission status. Editorial distinction: modular architecture (separate cart-mounted instrument arms) structurally distinct from Intuitive da Vinci monolithic design (single patient-side cart). Three editorial axes within one entity: international commercial soft-tissue surgical archetype + modular-architecture distinction from Intuitive's monolithic design + non-US market state. Cohort positioning: international commercial soft-tissue surgical archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance.
Modular architecture: separate cart-mounted arms (distinct from da Vinci monolithic)
Per DEPLOY's surgical cluster framework, Versius operates a modular architecture structurally distinct from Intuitive da Vinci's monolithic design. Versius (modular): separate cart-mounted instrument arms; each arm operates as an independent mobile unit; surgeons select 2-4 arms per procedure based on case requirements. Intuitive da Vinci (monolithic): single patient-side cart with 3-4 arms in fixed configuration; entire patient-side cart positioned as one unit. Per DEPLOY's framework, the modular-vs-monolithic architectural distinction is editorially significant at the cohort-architecture layer: trade-press coverage framing Versius as "another teleoperated soft-tissue system competing with da Vinci" operates at insufficient architectural-distinction scope.
International commercial deployment: EU + UK + Australia + India
Per DEPLOY's surgical cluster framework, Versius operates established commercial deployment volume across the European Union (multi-country commercial deployment); United Kingdom (home-market established commercial position); Australia (commercial deployment); India (commercial deployment). Per DEPLOY's framework, the international-commercial deployment framing is the load-bearing verified scope; the geographic-industrial-base distinction (UK-headquartered industrial base) extends the surgical cluster's structural cohort coverage beyond US-only market positioning.
Specific deployment figures cap-flagged pending CMR-disclosed primary source
Per cap-flag-as-trust-signal, specific deployment figures cap-flagged pending primary-source confirmation: aggregator-quoted deployment counts vs CMR-disclosed deployment counts may vary; CMR-disclosed primary-source confirmation is load-bearing. Per DEPLOY's framework, the international-commercial deployment framing operates as the load-bearing verified scope; specific deployment-count figures operate at lower verification posture pending primary-source confirmation. Trade-press coverage citing specific Versius unit counts without CMR primary-source confirmation operates outside DEPLOY's verification posture.
US FDA clearance state: cap-flag pending primary-source confirmation
Per DEPLOY's surgical cluster framework, US FDA clearance state operates at cap-flag posture pending primary-source confirmation of current submission status. Aggregator coverage on the US-market state varies (pending vs received vs Q4 2024 510(k) submission status); per cap-flag-as-trust-signal, the US-market framing requires precise primary-source verification at any specific verification claim. The non-US-market commercial deployment (established across EU + UK + Australia + India) is the load-bearing verified-commercial-deployment framing; the US market access state operates at honest-absence pending current primary-source confirmation.
Wave 2 expansion: three structural axes now live on surgical cluster
Per the surgical cluster framework, the CMR Versius + Moon Surgical Maestro Wave 2 expansion's structural point: Wave 1 covered general-laparoscopy variance across FDA-clearance states (Intuitive da Vinci cleared multi-procedure + J&J Ottava De Novo pre-market). Wave 2 extends into clinical-domain + commercial-model variance: CMR Versius international commercial soft-tissue + Moon Surgical Maestro assistive-laparoscopy. Three structural axes now live on surgical cluster: FDA-clearance-posture (Wave 1) + clinical-domain (Wave 2) + commercial-model (Wave 2).
CMR Versius: international commercial soft-tissue surgical archetype
CMR Versius is a modular soft-tissue surgical robotic system from CMR Surgical, a UK-based company founded in 2014. Per DEPLOY's surgical cluster framework, Versius anchors the international commercial soft-tissue surgical archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance.
CMR Surgical: UK-based, founded 2014
CMR Surgical is a UK-based surgical robotics company founded in 2014, headquartered in Cambridge. The CMR + Versius lineage represents the UK + European surgical robotics industrial base extending into the broader surgical cohort: distinct from US-headquartered cluster anchors (Intuitive Surgical + J&J Ottava) and from international cohort entries at distinct geographic-industrial-base layers.
Modular architecture (distinct from Intuitive monolithic design)
Per DEPLOY's surgical cluster framework, Versius operates a modular architecture structurally distinct from Intuitive da Vinci's monolithic design:
- Versius (modular): separate cart-mounted instrument arms; each arm operates as an independent mobile unit; surgeons select 2-4 arms per procedure based on case requirements.
- Intuitive da Vinci (monolithic): single patient-side cart with 3-4 arms in fixed configuration; the entire patient-side cart positioned as one unit at the operating table.
The modular-vs-monolithic architectural distinction is editorially significant at the cohort-architecture layer: trade-press coverage that frames Versius as "another teleoperated soft-tissue system competing with da Vinci" operates at insufficient architectural-distinction scope. Per DEPLOY's framework, the modular design enables distinct OR-footprint patterns + case-by-case arm-count configuration that differ structurally from monolithic deployment.
Commercial deployment: EU + UK + Australia + India (cap-flag specific figures)
Per DEPLOY's surgical cluster framework, Versius operates established commercial deployment volume across:
- European Union: multi-country commercial deployment.
- United Kingdom: home-market established commercial position.
- Australia: commercial deployment.
- India: commercial deployment.
Per cap-flag-as-trust-signal, specific deployment figures cap-flagged pending primary-source confirmation: aggregator-quoted deployment counts vs CMR-disclosed deployment counts may vary; CMR-disclosed primary-source confirmation is load-bearing. The international-commercial deployment framing is the load-bearing verified scope; specific deployment-count figures operate at lower verification posture pending primary-source confirmation.
US FDA clearance state: cap-flag pending primary-source confirmation
Per DEPLOY's surgical cluster framework, US FDA clearance state operates at cap-flag posture pending primary-source confirmation of current submission status (pending vs received vs Q4 2024 510(k) submission status varies across aggregator coverage). Per cap-flag-as-trust-signal, the US-market state framing requires precise primary-source verification at any specific verification claim.
Per DEPLOY's framework, the non-US-market commercial deployment (established across EU + UK + Australia + India) is the load-bearing verified-commercial-deployment framing; the US market access state operates at honest-absence pending current primary-source confirmation.
Cohort positioning: international commercial soft-tissue surgical archetype
Per the surgical cluster framework, CMR Versius anchors:
- International commercial soft-tissue surgical archetype: commercial deployment across EU + UK + Australia + India; UK-headquartered industrial base.
- Modular architecture distinction: separate cart-mounted instrument arms; distinct from Intuitive monolithic patient-side cart.
- US FDA clearance state at honest-absence posture: current submission status cap-flagged.
- Three structural editorial axes within one entity: international commercial + modular-architecture + non-US-market state.
Contrast with cohort:
- Intuitive da Vinci: market-leader installed-base anchor; 11,395 da Vinci systems + 1,041 Ion systems per SEC 10-Q; monolithic architecture.
- J&J Ottava: pre-market research tier; De Novo submission January 2026; FDA records "not authorized to be marketed."
- Moon Surgical Maestro: assistive-laparoscopy archetype; FDA 510(k) K240598 cleared Jun 2024; assistive-vs-replacement positioning.
The Wave 2 expansion's structural point: Wave 1 surgical FDA-clearance triangle covered general-laparoscopy variance across FDA-clearance states; Wave 2 extends into clinical-domain + commercial-model variance. Three structural axes now live on surgical cluster: FDA-clearance-posture (Wave 1) + clinical-domain (Wave 2) + commercial-model (Wave 2).
Consumer pricing surface for CMR Versius is forthcoming via Agent B's parallel surgical /price expansion; per cap-flag-as-trust-signal, the consumer-price-page is documented as forthcoming honest-absence pending Agent B's parallel ship. Registry institutional depth at CMR Surgical registry company + Versius registry model.
For the canonical surgical cluster context, see the surgical robotics cluster. For the market-leader installed-base context, see what is Intuitive Surgical da Vinci. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to CMR Versius: the 4-way autonomy-boundary taxonomy (replacement-robotics teleoperated tier; international commercial soft-tissue) + the 9-tier source-quality rubric (CMR IR + reputable-press + US FDA clearance state source classification).
Sources: Source: DEPLOY registry + surgical cluster framework + CMR Surgical company communications + FDA clearance database verification. Surgical cohort architecture + FDA-clearance-posture + commercial-model framework.
Frequently Asked Questions
What is CMR Versius?
CMR Versius is a modular soft-tissue surgical robotic system from CMR Surgical, a UK-based company founded in 2014. Per DEPLOY's surgical cluster framework, Versius anchors the international commercial soft-tissue surgical archetype within the surgical cluster: established commercial deployment volume across EU + UK + Australia + India; US FDA clearance state operates at cap-flag posture pending primary-source confirmation of submission status. Modular architecture (separate cart-mounted instrument arms) structurally distinct from Intuitive da Vinci monolithic design.
Who makes Versius?
CMR Surgical, a UK-based surgical robotics company headquartered in Cambridge, founded in 2014. The CMR + Versius lineage represents the UK + European surgical robotics industrial base extending into the broader surgical cohort: distinct from US-headquartered cluster anchors (Intuitive Surgical + J&J Ottava). Per DEPLOY's framework, the geographic-industrial-base distinction extends the surgical cluster's cohort coverage beyond US-only market positioning.
Is Versius cleared by the FDA?
US FDA clearance state operates at cap-flag posture pending primary-source confirmation per DEPLOY's surgical cluster framework. Aggregator coverage on the US-market state varies (pending vs received vs Q4 2024 510(k) submission status); per cap-flag-as-trust-signal, the US-market framing requires precise primary-source verification at any specific verification claim. The non-US-market commercial deployment (established across EU + UK + Australia + India) is the load-bearing verified-commercial-deployment framing; the US market access state operates at honest-absence pending current primary-source confirmation.
Where is Versius deployed?
Established commercial deployment across European Union + United Kingdom + Australia + India per DEPLOY's surgical cluster framework. Per cap-flag-as-trust-signal, specific deployment figures cap-flagged pending primary-source confirmation: aggregator-quoted deployment counts vs CMR-disclosed deployment counts may vary; CMR-disclosed primary-source confirmation is load-bearing. The international-commercial deployment framing is the load-bearing verified scope; specific deployment-count figures operate at lower verification posture pending primary-source confirmation.
What's the difference between Versius and da Vinci?
Architectural design + market positioning. Versius (modular): separate cart-mounted instrument arms; each arm operates as an independent mobile unit; surgeons select 2-4 arms per procedure; commercial deployment across EU + UK + Australia + India; US clearance state cap-flagged. Intuitive da Vinci (monolithic): single patient-side cart with 3-4 arms in fixed configuration; entire patient-side cart positioned as one unit at the OR table; market-leader installed-base (11,395 da Vinci + 1,041 Ion systems per SEC 10-Q). Per DEPLOY's surgical cluster framework, the modular-vs-monolithic architectural distinction is editorially significant at the cohort-architecture layer.
How much does Versius cost?
Consumer-surface pricing forthcoming via Agent B's parallel surgical /price expansion per DEPLOY's surgical cluster framework. The /price page operates at honest-absence pending Agent B's parallel ship per cap-flag-as-trust-signal. Per DEPLOY's framework, surgical-platform pricing operates at hospital-system + surgical-services-network procurement tier rather than consumer retail; aggregator-quoted unit pricing without CMR primary-source confirmation operates outside DEPLOY's verification posture. Registry institutional depth available at CMR Surgical registry company + Versius registry model.
CMR Versius verified as international commercial soft-tissue surgical archetype. CMR Surgical UK-based; founded 2014; Cambridge-headquartered. Modular architecture (separate cart-mounted instrument arms) structurally distinct from Intuitive da Vinci monolithic design (single patient-side cart). Established commercial deployment volume across European Union + United Kingdom + Australia + India; specific deployment figures cap-flagged pending CMR-disclosed primary-source confirmation. US FDA clearance state operates at cap-flag posture pending primary-source confirmation of current submission status. Three editorial axes within one entity: international commercial soft-tissue surgical archetype + modular-architecture distinction from Intuitive's monolithic design + non-US market state. Wave 2 expansion (CMR Versius + Moon Surgical Maestro) extends surgical cluster from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance. How DEPLOY verifies →
Continue reading
What is Intuitive Surgical da Vinci?
Market-leader installed-base anchor; 11,395 da Vinci + 1,041 Ion systems per SEC 10-Q; monolithic architecture.
Read article →
What is Johnson & Johnson Ottava?
Pre-market research-tier corporate-scale; De Novo submission January 2026; 'not authorized to be marketed.'
Read article →
What is Moon Surgical Maestro?
Assistive-laparoscopy archetype; FDA 510(k) K240598 cleared Jun 2024; assistive-vs-replacement positioning.
Read article →
The surgical robotics cluster
Surgical cohort framework; FDA-clearance + clinical-domain + commercial-model variance across three structural axes.
Read article →
Compare alternatives
CMR Surgical registry companyCMR Versius registry modelIntuitive da Vinci comparison explainerSurgical robotics cluster
More in surgical robotics
- How did DEPLOY correct the Moon Maestro FDA clearance date?
- How does DEPLOY distinguish da Vinci safety events at year-class-failure-mode-product-variant granularity?
- How does DEPLOY track supply-chain component failure modes chained to recall incidents?
- How does DEPLOY track the 2021 ROSA ONE Brain wrong-trajectory Class I recall?